Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Research Article

MR Imaging, MGMT Promoter Methylation Features and Prognostic Analysis of Subventricular Zone Contacting IDH Wild-type Glioblastoma

Author(s): Ruoyu Liu, Qi Liu, Kai Zhao, Minghang Liu, Guochen Sun and Bainan Xu*

Volume 19, Issue 12, 2023

Published on: 10 February, 2023

Article ID: e230123213010 Pages: 9

DOI: 10.2174/1573405619666230123114753

Price: $65

Abstract

Background: As the largest concentration of neural stem cells in adult brain, the subventricular zone (SVZ) is considered to be a potential source of glioblastoma (GBM) occurrence in recent years.

Methods: In this study, 116 patients with glioblastoma treated at PLA General Hospital were retrospectively reviewed. The features of SVZ contacting glioblastoma were analyzed in terms of MR imaging and MGMT promoter methylation. We also evaluated the prognostic value of SVZ contacting in GBM patients.

Results: GBM with SVZ involvement on MRI is more likely to grow across the midline (36.8% vs. 6.9%, P=0.002), more often multifocal lesion (35.6% vs. 6.9%, P=0.003) and have a lower proportion of MGMT promoter methylation (36.8% vs. 69.0%, P=0.003). The median overall survival and progression- free survival of patients in the SVZ contacting group were 12 months and 7 months, while 25 months and 17 months in the non-contacting group (P<0.001, respectively). There was no significant difference in overall survival (P=0.229) and progression-free survival (P=0.808) between patients with different SVZ contacting regions. Multivariate survival analysis indicated that patients with MRI SVZ involvement showed worse overall survival (HR=2.060, 95%CI 1.195-3.550,P=0.009) and progression- free survival (HR=3.021, 95%CI 1.788-5.104,P<0.001).

Conclusion: This study suggested that MRI SVZ involvement at diagnosis is an independent risk factor for overall survival and progression-free survival in IDH wild-type glioblastoma patients. Based on MR imaging, we also found that SVZ contacting glioblastomas had a larger proportion of crossing midline tumors and multifocal lesions. In addition, patients with SVZ contact in our research presented a lower proportion of MGMT promoter methylation.

Graphical Abstract

[1]
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
[http://dx.doi.org/10.1056/NEJMoa043330] [PMID: 15758009]
[2]
Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol 2013; 31(32): 4085-91.
[http://dx.doi.org/10.1200/JCO.2013.49.6968] [PMID: 24101040]
[3]
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370(8): 699-708.
[http://dx.doi.org/10.1056/NEJMoa1308573] [PMID: 24552317]
[4]
Lamborn KR, Yung WKA, Chang SM, et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncol 2008; 10(2): 162-70.
[http://dx.doi.org/10.1215/15228517-2007-062] [PMID: 18356283]
[5]
Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-oncol 2010; 12(2): 164-72.
[http://dx.doi.org/10.1093/neuonc/nop019] [PMID: 20150383]
[6]
Clarke JL, Ennis MM, Yung WKA, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncol 2011; 13(10): 1118-24.
[http://dx.doi.org/10.1093/neuonc/nor110] [PMID: 21813511]
[7]
Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370(8): 709-22.
[http://dx.doi.org/10.1056/NEJMoa1308345] [PMID: 24552318]
[8]
Lombard A, Digregorio M, Delcamp C, Rogister B, Piette C, Coppieters N. The subventricular zone, a hideout for adult and pediatric high-grade glioma stem cells. Front Oncol 2021; 10: 614930.
[http://dx.doi.org/10.3389/fonc.2020.614930] [PMID: 33575218]
[9]
Lee JH, Lee JE, Kahng JY, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 2018; 560(7717): 243-7.
[http://dx.doi.org/10.1038/s41586-018-0389-3] [PMID: 30069053]
[10]
Comas S, Luguera E, Molero J, et al. Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns. Clin Transl Oncol 2021; 23(3): 554-64.
[http://dx.doi.org/10.1007/s12094-020-02448-x] [PMID: 32728970]
[11]
Jungk C, Warta R, Mock A, et al. Location-dependent patient outcome and recurrence patterns in IDH1-wildtype glioblastoma. Cancers (Basel) 2019; 11(1): 122.
[http://dx.doi.org/10.3390/cancers11010122] [PMID: 30669568]
[12]
Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 2008; 62(3): 564-76.
[http://dx.doi.org/10.1227/01.neu.0000317304.31579.17] [PMID: 18425006]
[13]
Chen X, Xu B, Meng X, Zhang J, Yu X, Zhou D. Dual-room 1.5-T intraoperative magnetic resonance imaging suite with a movable magnet: Implementation and preliminary experience. Neurosurg Rev 2012; 35(1): 95-110.
[http://dx.doi.org/10.1007/s10143-011-0336-3] [PMID: 21674146]
[14]
Smith AW, Parashar B, Wernicke AG. Subventricular zone–associated glioblastoma: A call for translational research to guide clinical decision making. Neurogenesis 2016; 3(1): e1225548.
[http://dx.doi.org/10.1080/23262133.2016.1225548] [PMID: 27900341]
[15]
Mathew B, Kaliyath S, Krishnan J, Bhasi S. Impact of subventricular zone irradiation on outcome of patients with glioblastoma. J Cancer Res Ther 2018; 14(6): 1202-6.
[http://dx.doi.org/10.4103/jcrt.JCRT_295_17] [PMID: 30488830]
[16]
Rhoton AL Jr. The lateral and third ventricles. Neurosurgery 2002; 51(4): S207-71.
[PMID: 12234450]
[17]
Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012; 131(6): 1342-50.
[http://dx.doi.org/10.1002/ijc.27385] [PMID: 22139906]
[18]
Hallaert G, Pinson H, Van den Broecke C, et al. Subventricular zone contacting glioblastoma: Tumor size, molecular biological factors and patient survival. Acta Oncol 2020; 59(12): 1474-9.
[http://dx.doi.org/10.1080/0284186X.2020.1794032] [PMID: 32672481]
[19]
Liu S, Wang Y, Fan X, Ma J, Qiu X, Jiang T. Association of MRI-classified subventricular regions with survival outcomes in patients with anaplastic glioma. Clin Radiol 2017; 72(5): 426.e1-6.
[http://dx.doi.org/10.1016/j.crad.2016.11.013] [PMID: 28027779]
[20]
Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 2002; 3(8): 508-13.
[http://dx.doi.org/10.1016/S1470-2045(02)00820-3] [PMID: 12147437]
[21]
Bourekas EC, Varakis K, Bruns D, et al. Lesions of the corpus callosum: MR imaging and differential considerations in adults and children. Am J Roentgenol 2002; 179(1): 251-7.
[http://dx.doi.org/10.2214/ajr.179.1.1790251] [PMID: 12076946]
[22]
Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges. Neuro-oncol 2019; 21(2): 167-78.
[http://dx.doi.org/10.1093/neuonc/noy132] [PMID: 30189035]
[23]
Han Y, Yan LF, Wang XB, et al. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: A region of interest based analysis. BMC Cancer 2018; 18(1): 215.
[http://dx.doi.org/10.1186/s12885-018-4114-2] [PMID: 29467012]
[24]
Mistry AM, Hale AT, Chambless LB, Weaver KD, Thompson RC, Ihrie RA. Influence of glioblastoma contact with the lateral ventricle on survival: A meta-analysis. J Neurooncol 2017; 131(1): 125-33.
[http://dx.doi.org/10.1007/s11060-016-2278-7] [PMID: 27644688]
[25]
van Dijken BRJ, Jan van Laar P, Li C, et al. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma. J Neurosurg 2019; 131(3): 717-23.
[http://dx.doi.org/10.3171/2018.5.JNS18340] [PMID: 30485234]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy